Capricor FDA Review Spurs Optimism After Lancet Data

Capricor Therapeutics Inc. (NASDAQ: CAPR) said on Aug. 13 that its FDA review remains active as management prepares a Biologics License Application (BLA) amendment focused on HOPE‑3 data published in The Lancet. The company expects the amendment could prompt the FDA to extend the Aug. 22, 2026, Prescription Drug User Fee Act (PDUFA) action date.

FDA Review and BLA Amendment Plans

Capricor described deramiocel (CAP-1002) as its lead investigational cell therapy for Duchenne muscular dystrophy (DMD), with a regulatory focus shifting toward upper-limb skeletal muscle function. Management said on the Q2 earnings call that it is preparing a planned BLA amendment to refine the indication to upper-limb function and to include 24-month open-label extension data from the HOPE‑3 trial. The timing for submitting this amendment is still being finalized.

The company said the FDA has indicated willingness to review the amendment and, upon receipt, to extend the current PDUFA target action date. Deramiocel is in its second FDA review cycle following a Complete Response Letter (CRL) issued in July 2025 and a Class 2 resubmission.

HOPE‑3 Data and Regulatory Scrutiny

Capricor reported that the full HOPE‑3 Phase 3 dataset has been published in The Lancet after independent peer review. The trial was designed and powered to demonstrate efficacy in upper-limb function, with cardiac function as a key secondary endpoint. The primary endpoint, Performance of Upper Limb (PUL 2.0), was met with statistical significance (p=0.029), showing a mean relative benefit of 4.55%, equivalent to a 1.2-point absolute change. Management described this result as both statistically and clinically meaningful.

The Lancet publication reflects a re-analysis under a pre-specified statistical model. Under this approach, the full-population left ventricular ejection fraction (LVEF) lost statistical significance (p=0.09; treatment difference 1.8 percentage points), while the pre-specified cardiomyopathy subgroup remained significant (p=0.02). The primary endpoint for upper-limb function was unchanged.

FDA briefing documents released on July 27 raised concerns about changes Capricor made to its Statistical Analysis Plan (SAP) without prior submission, classifying some analyses as post-hoc and exploratory. The briefing described the product’s benefit-risk profile as unfavorable. The FDA Cellular, Tissue and Gene Therapies Advisory Committee met on July 29 and voted 3–9 that the available evidence did not provide substantial evidence of effectiveness for cardiomyopathy in DMD. The committee did not vote on the HOPE‑3 upper-limb primary endpoint; its feedback on upper-limb function was described by the company as directionally supportive. The committee’s recommendation is advisory.

Q2 Financials and Operational Runway

Capricor reported approximately $238 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Total operating expenses were about $42.9 million for the quarter, with a net loss of roughly $40.7 million, or $0.70 per share. Revenue remained zero, reflecting the company’s pre-commercial status.

The company said its cash position should fund operations for at least the next 12 months. It is moderating commercial spending while focusing resources on deramiocel. Some non-deramiocel pipeline activities have been paused.

Operating costs have increased as Capricor ramps clinical, regulatory, manufacturing, and commercial preparations for a potential launch. Management has deferred broader guidance pending greater regulatory clarity. The company’s near-term outlook depends on submitting the planned amendment, the FDA’s review of the additional 24-month data, and whether the agency extends the PDUFA action date.

“Deramiocel Biologics License Application (BLA) [is] under active FDA review.” — Capricor press release, Q2 2026